Alector (NASDAQ:ALEC – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Alector to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, risk, profitability, earnings and valuation.
Institutional & Insider Ownership
85.8% of Alector shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 8.3% of Alector shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Alector and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alector | 2 | 1 | 3 | 1 | 2.43 |
| Alector Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
Alector presently has a consensus target price of $5.10, indicating a potential upside of 117.95%. As a group, “Biotechnology” companies have a potential upside of 114.70%. Given Alector’s higher probable upside, equities research analysts plainly believe Alector is more favorable than its rivals.
Valuation and Earnings
This table compares Alector and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Alector | $173.47 million | -$142.93 million | 6.69 |
| Alector Competitors | $746.10 million | $10.34 million | -17.98 |
Alector’s rivals have higher revenue and earnings than Alector. Alector is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Alector has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Alector’s rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Profitability
This table compares Alector and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alector | 23.87% | 112.21% | 18.37% |
| Alector Competitors | -12,519.20% | -215.47% | -31.42% |
Summary
Alector beats its rivals on 8 of the 13 factors compared.
Alector Company Profile
Alector, Inc. is a biotechnology company based in South San Francisco, California, that develops investigational therapies for neurodegenerative diseases. Its research focuses on the role of the immune system in the brain and how immune pathways may be used to address disease processes. The company’s approach draws on human genetics and immunology to identify potential therapeutic targets. Its research has included programs targeting progranulin and TREM2, proteins associated with brain health and neurodegenerative disease.
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.
